Translational research that can rapidly transmit discoveries in the chemical laboratory to clinical application are critically important to the discovery of new chemotherapeutics. This proposal describes an established collaborative effort between a synthetic chemistry research group, a computational chemistry/biophysics research group, and a cardiology research group to develop a new class of matrix metalloproteinase inhibitors (MPIs) and to study these compounds in clinically relevant animal models of heart disease. Matrix metalloproteinases (MMPs) are an important class of hydrolytic enzymes involved in tissue restructuring and are implicated in a number of illnesses including cardiovascular disease, arthritis, and cancer. The research plan described herein represents a concerted series of experiments that will address MMP inhibitor design, synthesis, and evaluation under a highly interdisciplinary, collaborative effort that is already underway. Preliminary results show that several novel chelators inhibit MMP activity to a greater extent then the chelating moiety (hydroxamic acid) used in most MPIs studied to date. The design and synthesis of new MMP inhibitors derived from mechanism-based selection of zinc-binding groups (ZBGs) is proposed. Novel MPI compounds to be developed will ultimately be tested for their ability to improve the outcome of post- myocardial infarction changes in heart structure and function. Thus, the major objective of this proposal is to develop novel matrix metalloproteinase inhibitors by using a comprehensive bioinorganic approach that allows for the mechanistic elucidation of inhibitor-metalloprotein interactions and to translate basic discoveries in rational drug design to preclinical research using models of heart disease. The specific goals of this research program are: 1. To identify the molecular mechanisms of inhibitory activity of new MPIs using model complexes. 2. To synthesize and evaluate novel MPIs based on improved zinc-binding groups (ZBGs). 3. To evaluate novel MPIs using isolated working rat heart preparations. 4. To examine the effects of MPIs on in vivo ischemia reperfusion injury. ? ?

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
1R01HL080049-01A1
Application #
7037777
Study Section
Myocardial Ischemia and Metabolism Study Section (MIM)
Program Officer
Liang, Isabella Y
Project Start
2006-01-01
Project End
2010-11-30
Budget Start
2006-01-01
Budget End
2006-11-30
Support Year
1
Fiscal Year
2006
Total Cost
$379,172
Indirect Cost
Name
University of California San Diego
Department
Chemistry
Type
Schools of Arts and Sciences
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Jacobsen, Jennifer A; Fullagar, Jessica L; Miller, Melissa T et al. (2011) Identifying chelators for metalloprotein inhibitors using a fragment-based approach. J Med Chem 54:591-602
Daniel, Kevin B; Major Jourden, Jody L; Negoescu, Kimberly E et al. (2011) Activation of sulfonate ester based matrix metalloproteinase proinhibitors by hydrogen peroxide. J Biol Inorg Chem 16:313-23
Ramirez-Sanchez, Israel; Maya, Lisandro; Ceballos, Guillermo et al. (2010) Fluorescent detection of (-)-epicatechin in microsamples from cacao seeds and cocoa products: Comparison with Folin-Ciocalteu method. J Food Compost Anal 23:790-793
Agrawal, Arpita; Johnson, Sherida L; Jacobsen, Jennifer A et al. (2010) Chelator fragment libraries for targeting metalloproteinases. ChemMedChem 5:195-9
Rouffet, Matthieu; de Oliveira, César Augusto F; Udi, Yael et al. (2010) From sensors to silencers: quinoline- and benzimidazole-sulfonamides as inhibitors for zinc proteases. J Am Chem Soc 132:8232-3
Major Jourden, Jody L; Cohen, Seth M (2010) Hydrogen peroxide activated matrix metalloproteinase inhibitors: a prodrug approach. Angew Chem Int Ed Engl 49:6795-7
Schulze Wischeler, Johannes; Innocenti, Alessio; Vullo, Daniela et al. (2010) Bidentate Zinc chelators for alpha-carbonic anhydrases that produce a trigonal bipyramidal coordination geometry. ChemMedChem 5:1609-15
Major Jourden, Jody L; Cohen, Seth M (2010) Enzymatic activation of a matrix metalloproteinase inhibitor. Chem Commun (Camb) 46:1241-3
Villarreal, Francisco; Lew, Wilbur Y W (2010) Protein quality control in heart disease: using established drugs to target novel mechanisms. J Am Coll Cardiol 56:1427-9
Yan, Yi-Long; Miller, Melissa T; Cao, Yuchen et al. (2009) Synthesis of hydroxypyrone- and hydroxythiopyrone-based matrix metalloproteinase inhibitors: developing a structure-activity relationship. Bioorg Med Chem Lett 19:1970-6

Showing the most recent 10 out of 15 publications